AC
PPBT

Armistice Capital’s Purple Biotech PPBT Stock Holding History

Armistice Capital’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,800
Closed -$877K – 290
2024
Q3 		$877K Buy
15,800
+9,010
+133% +$680K 0.01% 175
2024
Q2 		$553K Sell
6,790
-3,785
-36% -$439K 0.01% 175
2024
Q1 		$1.42M Buy
10,575
+1,164
+12% +$167K 0.02% 152
2023
Q4 		$1.47M Buy
+9,411
New +$2.08M 0.02% 165

Other funds holding PPBT

KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CWM
Crowley Wealth Management Wilmington, Delaware $126M AUM 23.04% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Armistice Capital's PPBT Position: Q4 2024 in Review

Armistice Capital sold out of Purple Biotech (PPBT) in Q4 2024, closing a stake of 15,800 shares — an estimated $877K sold.

Armistice Capital first reported a position in PPBT in Q4 2023 and held it in 4 quarters. The position peaked at $1.47M in Q4 2023. 14 funds tracked by Wall St. Rank hold PPBT as of Q4 2024.

  • Armistice Capital reported no remaining Purple Biotech position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 15,800 Purple Biotech shares in Q4 2024, an estimated $877K.
  • Armistice Capital first reported a position in Purple Biotech in Q4 2023 and held it in 4 quarters.
  • Armistice Capital's Purple Biotech position peaked at $1.47M in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Purple Biotech as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.